[go: up one dir, main page]

TN2011000364A1 - Methods for treating acute myocardial infarctions and associated disorders - Google Patents

Methods for treating acute myocardial infarctions and associated disorders

Info

Publication number
TN2011000364A1
TN2011000364A1 TN2011000364A TN2011000364A TN2011000364A1 TN 2011000364 A1 TN2011000364 A1 TN 2011000364A1 TN 2011000364 A TN2011000364 A TN 2011000364A TN 2011000364 A TN2011000364 A TN 2011000364A TN 2011000364 A1 TN2011000364 A1 TN 2011000364A1
Authority
TN
Tunisia
Prior art keywords
methods
acute myocardial
associated disorders
treating acute
myocardial infarctions
Prior art date
Application number
TN2011000364A
Other languages
English (en)
Inventor
Jeff Olgin
Karl Kossen
Original Assignee
Intermune Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Univ California filed Critical Intermune Inc
Publication of TN2011000364A1 publication Critical patent/TN2011000364A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000364A 2009-01-26 2011-07-22 Methods for treating acute myocardial infarctions and associated disorders TN2011000364A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14734009P 2009-01-26 2009-01-26
PCT/US2010/022112 WO2010085805A1 (fr) 2009-01-26 2010-01-26 Méthodes de traitement d'infarctus du myocarde aigus et troubles associés

Publications (1)

Publication Number Publication Date
TN2011000364A1 true TN2011000364A1 (en) 2013-03-27

Family

ID=42354646

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000364A TN2011000364A1 (en) 2009-01-26 2011-07-22 Methods for treating acute myocardial infarctions and associated disorders

Country Status (16)

Country Link
US (2) US20100190731A1 (fr)
EP (1) EP2389227A4 (fr)
JP (1) JP2012515800A (fr)
KR (1) KR20110114684A (fr)
CN (1) CN102292124A (fr)
AP (1) AP2011005824A0 (fr)
AU (1) AU2010206543A1 (fr)
BR (1) BRPI1006979A2 (fr)
CA (1) CA2747251A1 (fr)
CL (1) CL2011001811A1 (fr)
IL (1) IL213526A0 (fr)
MX (1) MX2011007854A (fr)
NI (1) NI201100147A (fr)
SG (1) SG172981A1 (fr)
TN (1) TN2011000364A1 (fr)
WO (1) WO2010085805A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
EP2474533B1 (fr) 2009-05-25 2015-02-25 Central South University Préparation de composés de 1-(benzyl substitué)-5-trifluorométhyl-2-(1h)pyridone et de leurs sels, et leur utilisation
EP2436670B1 (fr) 2009-05-25 2014-04-16 Central South University Préparation de composés de 1-(aryl substitué)-5-trifluorométhyl-2-(1h)-pyridone et de leurs sels et leurs applications
PH12013500411A1 (en) * 2010-09-01 2022-03-30 Genzyme Corp Treatment of myocardial infarction using tgf - beta antagonists
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2670242B1 (fr) 2011-01-31 2022-03-16 Avalyn Pharma Inc. Composés analogues de pyridone et de pirfénidone en aérosol, et leurs utilisations
JP2014507474A (ja) 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
MX2013013752A (es) * 2011-05-25 2014-08-01 Intermune Inc Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.
EP2783016A1 (fr) 2011-11-22 2014-10-01 Intermune, Inc. Procédés de diagnostic et de traitement de la fibrose pulmonaire idiopathique
US9149200B2 (en) * 2012-05-08 2015-10-06 Northwestern University Using intracardiac electrograms to predict location of fibrosis and autonomic nerves in the heart
US9078918B2 (en) * 2012-05-08 2015-07-14 Northwestern University Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
KR102057877B1 (ko) * 2012-07-18 2019-12-20 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
JP6454348B2 (ja) 2013-12-19 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6525437B2 (ja) * 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
CN107922485A (zh) * 2015-06-15 2018-04-17 斯坦福大学托管董事会 诊断和治疗情绪障碍的方法
CN105085383B (zh) * 2015-08-19 2017-09-01 四川大学 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
CN105669562A (zh) * 2016-04-05 2016-06-15 叶芳 一种氟取代嘧啶类化合物及其制备方法
CN109311859B (zh) * 2016-04-14 2022-01-21 广州嘉越医药科技有限公司 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物
CN107556234A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型吡啶酮类化合物及其制备方法和在医学上的应用
WO2018124236A1 (fr) * 2016-12-27 2018-07-05 国立大学法人大阪大学 Composition pharmaceutique pour traitement de cardiopathie réfractaire
EP3612522A4 (fr) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. Composés thérapeutiques
ES3023840T3 (en) 2017-07-31 2025-06-03 Washington University St Louis Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
CN107641098A (zh) * 2017-09-06 2018-01-30 南阳师范学院 一种实现吡啶酮c6位烯基化的方法
CA3090270A1 (fr) * 2018-02-02 2019-08-08 Genentech, Inc. Compose pharmaceutique, sels de celui-ci, formulations de celui-ci, et procedes de fabrication et d'utilisation de celui-ci
EP3773187B1 (fr) * 2018-03-29 2025-02-19 Medtronic, Inc. Réglage et évaluation d'un dispositif d'assistance ventriculaire gauche
WO2019246521A1 (fr) * 2018-06-22 2019-12-26 Shire Human Genetic Therapies, Inc. Anticorps anti-flt-1 pour le traitement de la dysplasie bronchopulmonaire
EP4121049A4 (fr) * 2020-03-18 2024-04-03 Puretech Lyt 100, Inc. Procédés de traitement d'un lymphoedème avec de la deupirfénidone
CN117586227A (zh) * 2023-11-23 2024-02-23 广东中科药物研究有限公司 一种吡非尼酮衍生物及其制备方法与应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (fr) * 1972-12-18 1979-02-27 Affiliated Medical Research Pyridone n-substituee; methode generale de synthese des pyridones
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
US6114353A (en) * 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
JP2002526447A (ja) * 1998-09-18 2002-08-20 メファ・アクチェンゲゼルシャフト アルキルフェニルピリドンの局所製剤
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
JP2005528082A (ja) * 2001-12-18 2005-09-22 モンドバイオテック・ラボラトリーズ・アンスタルト 間質性肺疾患の治療を向上させるためのインターフェロンγ又はパーフェニドンと分子診断薬との新規医薬組成物
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
WO2004019863A2 (fr) * 2002-08-28 2004-03-11 Intermune, Inc. Therapie de combinaison pour le traitement de troubles fibrosants
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
DE10307650A1 (de) * 2003-02-21 2004-09-02 Endress + Hauser Gmbh + Co. Kg Verfahren zum Übertragen von Daten über einen Feldbus der Prozessautomatisierungstechnik
WO2005013917A2 (fr) * 2003-02-28 2005-02-17 Intermune, Inc. Therapie combinee servant a traiter une infection par un alphavirus et une fibrose hepatique
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
US20070032457A1 (en) * 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US20070172446A1 (en) * 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005000227A2 (fr) * 2003-06-06 2005-01-06 Intermune, Inc. Methodes permettant de traiter des troubles medies par tnf
WO2005040758A2 (fr) * 2003-10-24 2005-05-06 Intermune, Inc. Utilisation de pirfenidone dans des posologies therapeutiques
CA2545813C (fr) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. Derives de pyridone, et utilisation correspondante
WO2005067454A2 (fr) * 2003-12-23 2005-07-28 Valeant Pharmaceuticals North America Polytherapie pour le traitement de l'infection par le virus de l'hepatite c
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090041778A1 (en) * 2004-11-22 2009-02-12 Sukhatme Vikas P Methods And Compositions For The Treatment Of Graft Failure
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
HRP20141053T1 (hr) * 2005-05-10 2014-12-19 Intermune, Inc. Derivati piridona za moduliranje stresom aktiviranog sustava protein kinaze
CN101263156A (zh) * 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
ATE551057T1 (de) * 2005-10-31 2012-04-15 Intermune Inc Zusammensetzungen von pirfenidon/toll-like rezeptor (tlr)-antagonisten und verfahren zu ihrer verwendung zur stimulierung der produktion des granulozyten-kolonie-stimulierenden faktors (g-csf)
WO2007053610A2 (fr) * 2005-11-01 2007-05-10 The Regents Of The University Of California Traitement de la fibrillation auriculaire a base de pirfenidone
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
WO2007075388A2 (fr) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Procédés de traitement et de prévention locaux de troubles cardiaques
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
JP5558104B2 (ja) * 2006-12-11 2014-07-23 スリー−ディー マトリックス， インコーポレイテッド 心組織の保護および再生のための組成物および方法
SI2124945T1 (sl) * 2006-12-18 2011-08-31 Intermune Inc Postopek dajanja terapije s pirfenidonom pacientu
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CN102099036B (zh) * 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) * 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function

Also Published As

Publication number Publication date
EP2389227A1 (fr) 2011-11-30
CL2011001811A1 (es) 2011-11-11
CA2747251A1 (fr) 2010-07-29
BRPI1006979A2 (pt) 2016-04-12
IL213526A0 (en) 2011-07-31
KR20110114684A (ko) 2011-10-19
WO2010085805A1 (fr) 2010-07-29
EP2389227A4 (fr) 2012-08-08
CN102292124A (zh) 2011-12-21
US20100190731A1 (en) 2010-07-29
US20110218515A1 (en) 2011-09-08
MX2011007854A (es) 2011-08-15
JP2012515800A (ja) 2012-07-12
SG172981A1 (en) 2011-08-29
AU2010206543A1 (en) 2011-07-07
AP2011005824A0 (en) 2011-08-31
NI201100147A (es) 2011-11-09

Similar Documents

Publication Publication Date Title
TN2011000364A1 (en) Methods for treating acute myocardial infarctions and associated disorders
MY170713A (en) Treatment protocol of diabetes type 2
IN2015DN01156A (fr)
IN2014DN09805A (fr)
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2014DN09782A (fr)
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
PH12014501702A1 (en) Imidazopyrrolidinone compounds
IN2014DN09804A (fr)
MX2015004362A (es) Derivados de ketamina.
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
IN2015KN00449A (fr)
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.